DRIO — DarioHealth Corp.
Is DRIO overbought or oversold? Here is the current MarketMoodz read.
DarioHealth Corp. (DRIO) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Health Information Services) last closed at $1.15. The rating moved from Oversold to Strong Oversold on November 17, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$1.15
- Last changeMoved from Oversold to Strong Oversold on November 17, 2026
- SectorHealthcare
- IndustryHealth Information Services
See all oversold Healthcare stocks →
AI analysis
DarioHealth Corp. operates in a large, growing market for digital chronic-disease management with a subscription-style revenue model and several attractive demand drivers (diabetes care, employer/payor adoption, at-home treatment trends). The company’s forward path depends heavily on scaling enterprise contracts and maintaining retention to justify valuation. Near-term sector momentum and regulatory readthroughs are supportive, but macro and capital-market pressures plus competition and dilution risk create meaningful execution uncertainty. Monitor quarterly revenue cadence, gross-margin trends on enterprise deals, cash runway, and any material partnership or payor contract announcements as primary indicators of a positive or negative directional shift.
Key factors
- Recurring revenue model from chronic-disease management subscriptions provides predictable top-line lift if retention and enterprise sales scale
- Large addressable market in diabetes and hypertension management with multiple potential payor/employer channels
- Favorable sector flows into growth/healthcare innovation can support multiple near-term re-ratings if execution milestones are met
- Readthroughs from recent regulatory approvals (patch/tubeless insulin pumps, at-home treatments) increase market attention on diabetes/home-care solutions and potential partnership opportunities
- Partnerships and pilot programs with payors/employers are critical catalysts to convert trials into recurring revenue
Risks
- Cash burn and likelihood of future equity or convertible financing that could dilute existing shareholders
- Intense competition from larger digital-health players and integrated care vendors (incumbents and well-funded startups) that can win payor/employer contracts
- Execution risk converting pilots to scale, including price/reimbursement pressure from payors and Medicare Advantage dynamics
- Low liquidity and high share-price volatility common to micro-/small-cap digital health names
- Regulatory and data/privacy compliance requirements that can increase operational costs and slow deployments
See today's live rating, score and targets
Members see the live hourly rating for DRIO — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.